Interested in promotions? | Click here >>
9220
PhosphoPlus® ATF-2 (Thr71) Antibody Kit
Primary Antibodies
PhosphoPlus Antibody Kit

PhosphoPlus® ATF-2 (Thr71) Antibody Kit #9220

Citations (4)
other Image 1 - PhosphoPlus® ATF-2 (Thr71) Antibody Kit

After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.

To Purchase # 9220

Kit Usage Information

Protocols

Specificity / Sensitivity

Phospho-ATF-2 (Thr71) Antibody detects endogenous levels of ATF-2 only when phosphorylated at Thr71. It recognizes this site regardless of the phosphorylation state of Thr69. ATF-2 (20F1) Rabbit mAb detects endogenous levels of total ATF-2 protein. Neither antibody cross-reacts with c-Jun, CREB or other transcription factors.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr71 of human ATF-2 (Phospho-ATF-2 (Thr71) Antibody), or with a synthetic peptide corresponding to the amino terminal sequence of human ATF-2 (ATF-2 (20F1) Rabbit mAb). Antibodies are purified by protein A and peptide affinity chromatography.

Background

The transcription factor ATF-2 (also called CRE-BP1) binds to both AP-1 and CRE DNA response elements and is a member of the ATF/CREB family of leucine zipper proteins (1). ATF-2 interacts with a variety of viral oncoproteins and cellular tumor suppressors and is a target of the SAPK/JNK and p38 MAP kinase signaling pathways (2-4). Various forms of cellular stress, including genotoxic agents, inflammatory cytokines, and UV irradiation, stimulate the transcriptional activity of ATF-2. Cellular stress activates ATF-2 by phosphorylation of Thr69 and Thr71 (2-4). Both SAPK and p38 MAPK have been shown to phosphorylate ATF-2 at these sites in vitro and in cells transfected with ATF-2. Mutations of these sites result in the loss of stress-induced transcription by ATF-2 (2-4). In addition, mutations at these sites reduce the ability of E1A and Rb to stimulate gene expression via ATF-2 (2).

  1. Abdel-Hafiz, H.A. et al. (1992) Mol Endocrinol 6, 2079-89.
  2. Gupta, S. et al. (1995) Science 267, 389-93.
  3. van Dam, H. et al. (1995) EMBO J 14, 1798-811.
  4. Livingstone, C. et al. (1995) EMBO J 14, 1785-97.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PhosphoPlus is a trademark of Cell Signaling Technology, Inc.
LumiGLO is a registered trademark of Kirkegaard & Perry Laboratories.